177LuDOTATATE Rechallenge from the SEPTRALUSEMNIM Registry: Timing, Selection, Efficacy and Safety (EANM 2026) - Sep 29, 2026 - Abstract #OP-261; Pres time: Oct 18, 2026; 04:45 PM - 06:15 PM; Location: Hall G1; "RPRRT provides meaningful disease control with low highgrade toxicity. Long benefit from IPRRT, preserved SSTR expression, and good performance status are key selection factors. Consistent outcomes across tumor sites support RPRRT as a tumoragnostic strategy in NET sequencing."
Clinical • Endocrine Cancer • Neuroendocrine Neoplasm • Solid Tumor • SSTR
|
|
M. Mitjavila Casanovas 1; A. García Burillo 2; V. Pubul 3; S. Prado 4; J. Hernando 2; A. Prieto 1; Z. Noguerada 5; T. Aroui 6; M. Castellón 7; R. Valverde 8; F. Pena 9; B. Llana 10; M. Nevares 11; M. Velasco 12; L. Garcia-Cañamaque 13; J. Ardila 14; J. Arbizu 15; D. Balaguer 16; M. Orduña 17; A. Repetto 18; M. de la Rubia 19; M. Antón Leal 20; J. Vercher-Conejero 21; P. Jimenez-Fonseca 10; A. Carmona-Bayonas 22
|